BioLineRx is trading +9.80% at $2.80 after no clear company-specific catalyst was identified for September 10, 2026.
- The latest available company update concerns its September 23 annual shareholder meeting.
- Recent financial and financing announcements predate this move.
- The available market backdrop is mixed, so the pre-market gain remains unexplained.